Bindarit prolongs survival and reduces renal damage in NZB/W lupus mice

Clinical and Experimental Rheumatology

Volumn 16, Issue 2, 1998, Pages 149-154

  Guglielmotti, A ^a   Aquilini, L ^a   D'Onofrio, E ^a   Rosignoli, M T ^a   Milanese, C ^a   Pinza, M ^a  

^a Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

Author keywords

Bindarit; NZB W mice; Systemic lupus erythematosus

Indexed keywords

2 METHYL 2 [[1 (PHENYLMETHYL) 1H INDAZOL 3 YL]METHOXY]PROPANOIC ACID; BINDARIT; CYCLOPHOSPHAMIDE; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; KIDNEY INJURY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0031778368     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. HOWIE JB, HELYER BJ : The immunology and pathology of NZB mice. Adv Immunol 1968; 9: 215-66.
2. ANDREWS BS, EISENBERG RA, THEOFILOPOULOS AN, et al.: Spontaneous murine lupus-like syndromes. J Exp Med 1978; 148: 1198-215.
3. THEOFILOPOULOS AN, DIXON FJ: Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269-387.
4. HOROWITZ RE, DUBOIS EK, WEINER J, et al.: Cyclophosphamide treatment of mouse systemic lupus erythematosus. J Lab Invest 1969; 21: 199-206.
5. HAHN BH, BAGBY MK, HAMILTON TR: Comparison of therapeutic immunosuppressive effects of azathioprine, prednisolone and combined therapy in NZB/NZW mice. Arthritis Rheum 1973; 16: 163-70.
6. STEINBERG AD, GELFAND MC, HARDIN JA, LOWENTHAL T: Therapeutic studies in NZB/ W mice - III. Relationship between renal status and efficacy of immunosuppressive drug therapy. Arthritis Rheum 1975; 18: 9-14.
7. CASEY TP: Azathioprine (Imuran) administration and the development of malignant lymphomas in NZB mice. Clin Exp Immunol 1968; 3: 305-12.
8. DECKER JL: Toxicity of immunosuppressive drugs in man. Arthritis Rheum 1973; 16: 89-91.
9. WALKER SE, BOLE GG Jr: Augmented incidence of neoplasia in NZB/NZW mice treated with long term cyclophosphamide. J Lab Clin Med 1973; 82: 619-33.
10. WALKER SE, ANVER MR: High incidence of neoplasms in female NZB/W mice treated with pulse doses of cyclophosphamide. Vet Immunol Immunopathol 1983; 5: 97-104.
11. MILLER JJ, WILLIAMS GF, LEISSRING JC: Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. Am J Med 1971; 50: 530-5.
12. QURESHI MSA, GOLDSMITH HJ, PENNINGTON JH, et al.: Cyclophosphamide therapy and sterility. Lancet 1972; 2: 1290-1.
13. CIOLI V, CIARNIELLO MG, GUGLIELMOTTI A, et al.: A new protein antidenaturant agent, bindarit, reduces secondary phase of adjuvant arthritis in rats. J Rheumatol 1992; 19: 1735-42.
14. SASO L, SILVESTRINI B, ZWAIN I, et al.: Abnormal glycosylation of hemopexin in arthritic rats can be blocked by bindarit. J Rheumatol 1992; 19: 1859-67.
15. GUGLIELMOTTI A, SILVESTRINI B, SASO L, ZWAIN I, CHENG YC: Chronic inflammatory response in the rat can be blocked by bindarit. Biochem. Molec Biol Intl 1993; 29: 747-56.
16. GUGLIELMOTTI A, ROSIGNOLI MT, AQUILINI A, MILANESE C: Effects of bindarit in murine lupus disease. Lupus 1995; 4: 115.
17. REMUZZI G, VIGANÒ G, GOTTI E, TADDEI I, CORPETTI G, DIONISIO P: Bindarit, a new potential therapeutic agent for lupus nephritis: A pilot study. Lupus 1995; 4: 99.
18. VIGANÒ G, GOTTI E, CASIRAGHI F, et al.: Bindarit reduces urinary albumin excretion (UAE) and urinary interleukin-6 (IL-6) in patients with proliferative lupus nephritis. J Am Soc Nephrol 1995; 6: 434.
19. READ SM, NORTHCOTE DH: Minimization of variation in the response to different proteins of the Coomassie blue G dye-binding assay for protein. Anal Biochem 1981; 116: 53-64.
20. MORRIS AD, ESTERLY J, CHASE G, SHARP GC: Cyclophosphamide protection in NZB/ NZW disease. Arthritis Rheum 1976; 19: 49-55.
21. GELFAND MC, STEINBERG AD, NAGLE R, KNEPSHIELD JH: Therapeutic studies in NZB/W mice. I. Synergy of azathioprine, cyclophosphamide and methylprednisolone in combination. Arthritis Rheum 1972; 15: 239-46.
22. 1 mice. Proc Natl Acad Sci USA 1978; 75: 1500-4.
23. 1 mice. J Clin Invest 1981; 68: 556-9.
24. ROUBINIAN JR, PAPOIAN R, TALAL N: Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J Clin Invest 1977; 59: 1066-70.
25. VERHEUL HAM, SCHOT GH, DECKERS GHJ, SCHUURS AHW: Effects of tibolone, lynestrenol, ethylestrenol and desogestrel on autoimmune disorders in NZB/W mice. Clin Immunol Immunopathol 1986; 38: 198-208.
26. GUGLIELMOTTI A, COLETTA I, MILANESE C, et al.: Bindarit effects on MCP-1 and IL-6: A potential mechanism for renal injury protection. J Am Soc Nephrol 1997; 8: 473A.
27. CORNA D, ZOJA C, BENEDETTI G, et al.: Bindarit limits renal injury and prolongs survival in murine lupus autoimmune disease. J Am Soc Nephrol 1997; 8: 470A.
28. LINKER-ISRAELI M, DEANS RJ, WALLACE DJ, PREHN J, OZERI-CHEN T, KLINENBERG JR: Elevated levels of endogenous IL-6 in systemic lupus erythematosus. J Immunol 1991; 147: 117-23.
29. IWANO M, DOHI K, HIRATA E, et al.: Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol 1993; 40: 16-21.
30. NORIS M, BERNASCONI S, CASIRAGHI F, et al.: Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995; 73: 804-9.
31. ZOJA C, XUE-HUI L, DONADELLI R, et al.: Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 1997; 8: 720-9.